Human LTC-IC can be maintained for at least 5 weeks in vitro when interleukin-3 and a single chemokine are combined with O-sulfated heparan sulfates: Requirement for optimal binding interactions of heparan sulfate with early-acting cytokines and matrix proteins

Blood

Volumn 95, Issue 1, 2000, Pages 147-155

  Gupta, Pankaj ^a   Oegema Jr , Theodore R ^b   Brazil, Joseph J ^b   Dudek, Arkaduisz Z ^b   Slungaard, Arne ^b   Verfaillie, Catherine M ^b  

^a VA MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEPARAN SULFATE; INTERLEUKIN 3; MATRIX PROTEIN;

ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; GROWTH REGULATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0033957697     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.1.147.001k28_147_155     Document Type: Article

References (65)

1. Lowry PA, Deacon D, Whitefield P, McGrath HE, Quesenberry PJ. Stem cell factor induction of in vitro murine hematopoietic colony formation by "subliminal" cytokine combinations: the role of "anchor factors." Blood. 1992;80:663-669.
2. Lemischka IR. Microenvironmental regulation of hematopoietic stem cells. Stem Cells. 1997;15: 63-68.
3. Moore KA, Pytowski B, Witte L, Hicklin D, Lemischka IR. Hematopoietic activity of a stromal cell transmembrane protein containing epidermal growth factor-like repeat motifs. Proc Natl Acad Sci U S A. 1997;94:4011-4016.
4. Moore KA, Ema H, Lemischka IR. In vitro maintenance of highly purified, transplantable hematopoietic stem cells. Blood. 1997;89:4337-4347.
5. Long MW, Briddell R, Walter AW, Bruno E, Hoffman R. Human hematopoietic stem cell adherence to cytokines and matrix molecules. J Clin Invest. 1992;90:251-255.
6. Lyon M, Deakin JA, Mizuno K, Nakamura T, Gallagher JT. Interaction of hepatocyte growth factor with heparan sulfate: elucidation of the major heparan sulfate structural determinants. J Biol Chem. 1994;269:11,216-11,223.
7. Maccarana M, Lindahl U. Mode of interaction between platelet factor 4 and heparin. Glycobiology. 1993;3:271-277.
8. Ornitz DM, Herr AB, Nilsson M, Westman J, Svahn C-M, Waksman G. FGF binding and FGF receptor activation by synthetic heparan-derived di- and trisaccharides. Science. 1995;268:432-436.
9. Roberts R, Gallagher J, Spooncer E, Allen TD, Bloomfield F, Dexter RM. Heparan sulphate bound growth factors: a mechanism for stromal cell mediated haemopoiesis. Nature. 1998;332: 376-378.
10. Schon P, Vischer P, Volker W, Schmidt A, Faber V. Cell-associated proteoheparan sulfate mediates binding and uptake of thrombospondin in cultured porcine vascular endothelial cells. Eur J Cell Biol. 59:329-339.
11. Sun X, Kaesberg PR, Choay J, Harenberg J, Ershler WB, Mosher DF. Effects of sized heparin oligosaccharides on the interactions of Chinese hamster ovary cells with thrombospondin. Semin Thromb Hemost. 1992;18:243-251.
12. Corless CL, Mendoza A, Collins T, Lawler J. Colocalization of thrombospondin and syndecan during murine development. Dev Dyn. 1992;193: 346-358.
13. Brunner G, Gabrilove J, Rifkin DB, Wilson EL. Phospholipase C release of basic fibroblast growth factor from human bone marrow cultures as a biologically active complex with a phosphatidylinositol-anchored heparan sulfate proteoglycan. J Cell Biol. 1991;114:1275-1283.
14. San Antonio JD, Slover J, Lawler J, Karnovsky MJ, Lander AD. Specificity in the interactions of extracellular matrix proteins with subpopulations of the glycosaminoglycan heparin. Biochemistry. 1993;32:4746-4755.
15. Lee KB, al-Hakim A, Loganathan D, Linhardt RJ. A new method for sequencing linear oligosaccharides on gels using charged, fluorescent conjugates. Carbohydr Res. 1991;214:155-168.
16. Graham GJ, Wright EG, Hewick R, et al. Identification and characterization of an inhibitor of haemopoietic stem cell proliferation. Nature. 1990; 344:442-444.
17. Kennedy M, Firpo M, Choi K, et al. A common precursor for primitive erythropoiesis and definitive haematopoiesis. Nature. 1997;386:488-493.
18. Fiebich BL, Jager B, Schollmann C, et al. Synthesis and assembly of functionally active human vascular endothelial growth factor homodimers in insect cells. Eur J Biochem. 1993;211:19-26.
19. Gitay-Goren H, Soker S, Vlodavsky I, Neufeld G. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J Biol Chem. 1992;267:6093-6098.
20. Nakayama N, Fang I, Elliott G. Natural killer and B-lymphoid potential in CD34+ cells derived from embryonic stem cells differentiated in the presence of vascular endothelial growth factor. Blood. 1998;91:2283-2295.
21. Faham S, Hileman RE, Fromm JR, Linhardt RJ, Rees DC. Heparin structure and interactions with basic fibroblast growth factor. Science. 1996;271: 1116-1120.
22. Kato M, Wang H, Kainulainen V, et al. Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nature Med. 1998;4:691-697.
23. Rahmoune H, Rudland PS, Gallagher JT, Fernig DG. Hepatocyte growth factor/scatter factor has distinct classes of binding site in heparan sulfate from mammary cells. Biochemistry. 1998;37: 6003-6008.
24. Stringer SE, Gallagher JT. Specific binding of the chemokine platelet factor 4 to heparan sulfate. J Biol Chem. 1997;272:20,508-20,514.
25. Feyzi E, Saldeen T, Larsson E, Lindahl U, Salmivirta M. Age-dependent modulation of heparan sulfate structure and function. J Biol Chem. 1998; 273:13,395-13,398.
26. Gupta P, Oegema TR, Brazil JJ, Dudek AZ, Slungaard A, Verfaillie CM. Structurally specific heparan sulfates support primitive human hematopoiesis by formation of a multimolecular stem cell niche. Blood. 1998;92:4641-4651.
27. Verfaillie CM. Soluble factor(s) produced by human bone marrow stroma increase cytokine-induced proliferation and maturation of primitive hematopoietic progenitors while preventing their terminal differentiation. Blood. 1993;82:2045-2053.
28. Verfaillie CM. Direct contact between human primitive hematopoietic progenitors and bone marrow stroma is not required for long-term in vitro hematopoiesis. Blood. 1992;79:2821-2826.
29. Verfaillie CM, Catanzarro PM, Li W. Macrophage inflammatory protein-1α, interleukin 3 and diffusible marrow stromal factors maintain human hematopoietic stem cells for at least eight weeks in vitro. J Exp Med. 1994;179:643-649.
30. Bhatia R, McGlave PB, Miller JS, Wissink S, Lin WN, Verfaillie CM. A clinically suitable ex vivo expansion culture system for LTC-IC and CFC using stroma-conditioned medium. Exp Hematol. 1997; 25:980-991.
31. Broxmeyer HE, Sherry B, Cooper S, et al. Comparative analysis of the human macrophage inflammatory protein family of cytokines (chemokines) on proliferation of human myeloid progenitor cells: interacting effects involving suppression, synergistic suppression, and blocking of suppression. J Immunol. 1993;150:3448-3458.
32. Miller JS, McCullar V, Verfaillie CM. Ex vivo culture of CD34+/Lin-/DR-cells in stroma-derived soluble factors, interleukin-3, and macrophage inflammatory protein-1 alpha maintains not only myeloid but also lymphoid progenitors in a novel switch culture assay. Blood. 1998;91:4516-4522.
33. 0 and entry into the cell cycle of primitive human hematopoietic progenitors. Proc Natl Acad Sci U S A. 1992; 89:4013-4017.
34. Gupta P, McCarthy JB, Verfaillie CM. Stromal fibroblast heparan sulfate is required for cytokine-mediated ex vivo maintenance of human long-term culture-initiating cells. Blood. 1996;87:3229-3236.
35. Gordon MY, Riley GP, Watt SM, Greaves MF. Compartmentalization of a haematopoietic growth factor (GM-CSF) by glycosaminoglycans in the bone marrow microenvironment. Nature. 1987;326:403-405.
36. Alvarez-Silva M, Borojevic R. GM-CSF and IL-3 activities in schistosomal liver granulomas are controlled by stroma-associated heparan sulfate proteoglycans. J Leukoc Biol. 1996;59:435-441.
37. Bruno E, Luikart SD, Long MW, Hoffman R. Marrow-derived heparan sulfate proteoglycan mediates the adhesion of hematopoietic progenitor cells to cytokines. Exp Hematol. 1995;23:1212-1217.
38. Long MW, Dixit VM. Thrombospondin functions as a cytoadhesion molecule for human hematopoietic progenitor cells. Blood. 1990;75:2311-2318.
39. Chen YZ, Incardona F, Legrand C, Momeux L, Caen J, Han ZC. Thrombospondin, a negative modulator of megakaryocytopoiesis. J Lab Clin Med. 1997;129:231-238.
40. Sanderson PN, Nieduszynski IA, Huckerby TN. Very-high-field nmr studies of bovine lung heparan sulfate oligosaccharides produced by nitrous acid deaminative cleavage. Biochem J. 1983;211: 677-682.
41. Maccarana M, Sakura Y, Tawada A, Yoshida K, Lindahl U. Domain structure of heparan sulfates from bovine organs. J Biol Chem. 1996;271: 17,804-17,810.
42. Danishefsky I, Tzeng F, Ahrens M, Klein S. Synthesis of heparin-sepharoses and their binding with thrombin and antithrombin-heparin cofactor. Thromb Res. 1976;8:131-140.
43. Verfaillie CM, Blakolmer K, McGlave P. Purified primitive human hematopoietic progenitor cells with long-term in vitro repopulating capacity adhere selectively to irradiated bone marrow stroma. J Exp Med. 1990;172:509-512.
44. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J Immunol. 1981;126:1614-1619.
45. Lee MK, Lander AD. Analysis of affinity and structural selectivity in the binding of proteins to glycosaminoglycans: development of a sensitive electrophoretic approach. Proc Natl Acad Sci U S A. 1991;88:2768-2772.
46. Mach H, Volkin DB, Burke CJ, et al. Nature of the interaction of heparin with acidic fibroblast growth factor. Biochemistry. 1993;32:5480-5489.
47. Fisher RJ, Fivash M. Surface plasmon resonance based methods for measuring the kinetics and binding affinities of biomolecular interactions. Curr Opin Biotechnol. 1994;5:389-395.
48. Gitay-Goren H, Cohen T, Tessler S, et al. Selective binding of VEGF121 to one of the three vascular endothelial growth factor receptors of vascular endothelial cells. J Biol Chem. 1996;271: 5519-5523.
49. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell. 1993;4:1317-1326.
50. Rahmoune H, Chen HL, Gallagher JT, Rudland PS, Fernig DG. Interaction of heparan sulfate from mammary cells with acidic fibroblast growth factor (FGF) and basic FGF. Regulation of the activity of basic FGF by high and low affinity binding sites in heparan sulfate. J Biol Chem. 1998; 273:7303-7310.
51. Punzel M, Miller JS, Moore KA, Lemischka IR, Verfaillie CM. Culture of human CD34+/HLA-DR-/LIN-cells for 4 weeks on the AFT024 stromal cell line results in extensive amplification of CD34+ cells with 3-100 fold expansion of LTC-IC, CFC and primitive lymphoid progenitors [abstract]. Blood. 1997;90(10 suppl 1):161a.
52. Punzel M, Wissink S, Asleson K, et al. Development of an in vitro assay that can enumerate generative multilineage-initiating cells (ML-IC) in adult human BM [abstract]. Exp Hematol. 1998; 26:693.
53. Thiemann FT, Moore KA, Smogorzewska EM, Lemischka IR, Crooks GM. The murine stromal cell line AFT024 acts specifically on human CD34+CD38-progenitors to maintain primitive function and immunophenotype in vitro. Exp Hematol. 1998;26:612-619.
54. Punzel M, Gupta P, Roodell M, Mortari F, Verfaillie CM. Factor(s) secreted by AFT024 fetal liver cells following stimulation with human cytokines, are important for human LTC-IC growth. Leukemia 1999;7:1079-1084.
55. Matsunaga T, Hirayama F, Yonemura Y, Murray R, Ogawa M. Negative regulation by interleukin-3 (IL-3) of mouse early B-cell progenitors and stem cells in culture: transduction of the negative signals by betac and betaIL-3 proteins of IL-3 receptor and absence of negative regulation by granulocyte-macrophage colony-stimulating factor. Blood. 1998;92:901-907.
56. Yonemura Y, Ku H, Hirayama F, Souza LM, Ogawa M. Interleukin 3 or interleukin 1 abrogates the reconstituting ability of hematopoietic stem cells. Proc Natl Acad Sci U S A. 1996;93:4040-4044.
57. Otsuka T, Thacker JD, Eaves CJ, Hogge DE. Differential effects of microenvironmentally presented interleukin 3 versus soluble growth factor on primitive human hematopoietic cells. J Clin Invest. 1991;88:417-422.
58. Burroughs J, Gupta P, Blazar BR, Verfaillie CM. Diffusible factors from the murine cell line M2-10B4 support human in vitro hematopoiesis. Exp Hematol. 1994;22:1095-1101.
59. Kittler EL, McGrath H, Temeles D, Crittenden RB, Kister VK, Quesenberry PJ. Biologic significance of constitutive and subliminal growth factor production by bone marrow stroma. Blood. 1992;79: 3168-3178.
60. Modrowski D, Lomri A, Marie PJ. Glycosaminoglycans bind granulocyte-macrophage colony-stimulating factor and modulate its mitogenic activity and signaling in human osteoblastic cells. J Cell Physiol. 1998;177:187-195.
61. Spivak-Kroizman T, Lemmon MA, Dikic I, et al. Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. Cell. 1994; 79:1015-1024.
62. Muther H, Kuhlcke K, Gessner A, Abdallah S, Lother H. Homodimeric murine interleukin-3 agonists indicate that ligand dimerization is important for high-affinity receptor complex formation. Growth Factors. 1994;10:17-27.
63. Yang L, Yang Y-C. Heparin inhibits the expression of interleukin-11 and granulocyte-macrophage colony-stimulating factor in primate bone marrow stromal fibroblasts through mRNA destabilization. Blood. 1995;86:2526-2533.
64. Salmivirta M, Lidholt K, Lindahl U. Heparan sulfate: a piece of information. FASEB J. 1996;10: 1270-1279.
65. Wang H, Toida T, Kim YS, et al. Glycosaminoglycans can influence fibroblast growth factor-2 mitogenicity without significant growth factor binding. Biochem Biophys Res Commun. 1997;235: 369-373.